Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Caudill Cortney 2. Date of Event Requiring Statement (Month/Day/Year) 10/01/2025 3. Issuer Name and Ticker or Trading Symbol HALOZYME THERAPEUTICS, INC. [HALO] (Last) (First) (Middle) C/O HALOZYME THERAPEUTICS, INC., 12390 EL CAMINO REAL 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) SVP, CHIEF OPERATING OFFICER 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) SAN DIEGO, CA 92130 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock 7,674 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	11/01/2024(1)	11/01/2033	Common Stock	89,224	$33.51	D
Option to Purchase Common Stock	02/20/2026(1)	02/20/2035	Common Stock	11,302	$57.44	D
Restricted Stock Unit	11/01/2024(2)	(2)	Common Stock	27,977	$0	D
Restricted Stock Unit	02/20/2026(2)	(2)	Common Stock	10,664	$0	D
Performance Stock Unit	02/23/2027(3)	(3)	Common Stock	2,237	$0	D
Performance Stock Unit	02/23/2027(3)	(3)	Common Stock	9,246	$0	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Caudill Cortney C/O HALOZYME THERAPEUTICS, INC. 12390 EL CAMINO REAL SAN DIEGO, CA 92130			SVP, CHIEF OPERATING OFFICER

Signatures

/s/ James R. Oehler, Attorney-in-Fact		10/06/2025
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	This option vests one-fourth on such date and then vests 1/48th monthly thereafter.
(2)	One-fourth of the original grant vests on such date and one-fourth vests annually thereafter. Represents a restricted stock unit award with no exercise price.
(3)	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2024. This PSU holding represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.
Remarks: Exhibit List: Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.